Where to inject tirzepatide: the three FDA-approved subcutaneous sites are the abdomen (at least two inches away from the navel), the front of the thigh, and the back of the upper arm. Tirzepatide is a once-weekly injection. All three sites deliver similar drug exposure, so the choice depends on comfort, reach, and a simple rotation plan to protect your skin.
The Three Approved Sites
| Site | Specific Area | Notes |
|---|---|---|
| Abdomen | Either side of the belly, at least 2 inches from the navel | Easiest to reach; plenty of subcutaneous tissue |
| Thigh | Front (anterior) upper leg, mid-thigh region | Comfortable, easy to self-administer seated |
| Upper arm | Back (posterior) of the upper arm, fatty area | Often needs help from another person |
How Subcutaneous Injection Works
Tirzepatide is injected into the subcutaneous fat layer just beneath the skin, not into muscle or a vein. This layer absorbs the drug slowly and steadily, allowing the weekly dosing schedule. The pen or syringe used for tirzepatide is designed to deposit medication at the correct depth when the needle is inserted perpendicular to the skin. Intramuscular injection would speed absorption and is not recommended; intravenous injection is contraindicated.
Why Site Rotation Matters
- Reduces injection-site reactions (redness, itching, bruising)
- Prevents lipohypertrophy, a firm thickening of subcutaneous tissue that can alter drug absorption over time
- Minimizes discomfort if one area becomes tender
- Gives the skin time to recover between injections
A simple rotation plan: use the left abdomen one week, right abdomen the next, left thigh, right thigh, then the arms. Alternatively, move clockwise around the abdomen. The exact pattern is less important than consistency.
Step-by-Step Technique Basics
- Wash your hands.
- Take the pen or vial out of the refrigerator; let it reach room temperature for 30 minutes if possible (not required, but reduces stinging).
- Check the liquid: it should be clear to slightly yellow and free of particles.
- Clean the injection site with an alcohol wipe and let it air dry.
- Pinch or stretch the skin depending on the pen device used; follow the instructions that came with your pen.
- Insert the needle straight in and hold the pen against the skin until the dose indicator confirms delivery.
- Dispose of the pen or syringe in a sharps container. Never reuse needles.
For detailed written instructions, reference the FDA prescribing information for Mounjaro or Zepbound and the patient instructions for use that came with your pen.
What to Avoid
- Do not inject into a muscle, vein, or area with bruising, swelling, or scarring
- Do not inject within two inches of the navel
- Do not inject into moles, tattoos, or skin lesions
- Do not rub the site after injection
- Do not reuse needles or pens
- Do not freeze the medication; refrigerate at 36-46 degrees F until use
Storage and Handling
Store pens in the refrigerator until needed. Once removed, a pen can be kept at room temperature (below 86 degrees F) for up to 21 days. Do not freeze; discard the pen if it has been frozen. Keep it in the original carton to protect from light. If you travel, insulated cases designed for GLP-1 pens are widely available.
What to Do About Injection-Site Reactions
Mild redness or a small bump after injection is common and usually resolves within a day or two. Use a cool compress for comfort. If you notice persistent hardening, significant pain, warmth, or spreading redness, contact your prescriber. Allergic-type reactions (hives, swelling of the lips or tongue, trouble breathing) are rare but require emergency care.
Missed Doses
If you miss a dose and fewer than four days have passed, inject as soon as you remember and resume your regular schedule. If more than four days have passed, skip that dose and take the next one on your usual day. Never inject two doses close together to make up for a missed one. If you miss multiple consecutive weeks, your clinician may recommend restarting at a lower dose.
Tirzepatide and Prediabetes
Tirzepatide (as Zepbound or Mounjaro) is not FDA-approved specifically for prediabetes, but weight loss of 15 to 22 percent often moves A1C back to the normal range. If you are exploring treatment options for prediabetes, start with our treatment overview and prediabetes 101 resources to discuss with your clinician.
The Bottom Line
Where to inject tirzepatide comes down to three approved subcutaneous sites: abdomen, thigh, or upper arm. Rotate among them, use correct technique, and store the medication properly. Absorption is similar across sites, so comfort and consistency matter more than site choice. Follow your pen’s instructions for use and check in with your prescriber if you have questions about technique or reactions.
Medical disclaimer: This article is for educational purposes and is not medical advice. Always follow the prescribing information and guidance from your clinician.
